| 35.1 2.91 (9.04%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 44.9 |
1-year : | 52.45 |
| Resists | First : | 38.45 |
Second : | 44.9 |
| Pivot price | 33.24  |
|||
| Supports | First : | 33.08 |
Second : | 29.77 |
| MAs | MA(5) : | 34.09 |
MA(20) : | 33.71 |
| MA(100) : | 27.76 |
MA(250) : | 16.5 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 61.8 |
D(3) : | 58.1 |
| RSI | RSI(14): 55.1 |
|||
| 52-week | High : | 42.39 | Low : | 5.66 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ RAPT ] has closed below upper band by 23.3%. Bollinger Bands are 9.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 35.48 - 35.65 | 35.65 - 35.8 |
| Low: | 31.62 - 31.8 | 31.8 - 31.96 |
| Close: | 34.8 - 35.11 | 35.11 - 35.38 |
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Wed, 14 Jan 2026
RAPT Therapeutics Showcases Ozureprubart Progress, Strengthened Outlook - TipRanks
Wed, 14 Jan 2026
RAPT Therapeutics, Inc. Announces Participation in JPM Healthcare Conference - TradingView — Track All Markets
Wed, 07 Jan 2026
RAPT Therapeutics to Present Company Overview at 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
Wed, 07 Jan 2026
RAPT Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Thu, 25 Dec 2025
RAPT Therapeutics (RAPT) Is Up 8.0% After Index Additions And Trial Progress News Has The Bull Case Changed? - simplywall.st
Mon, 15 Dec 2025
RAPT Therapeutics, Inc. (NASDAQ:RAPT) surges 5.3%; individual investors who own 34% shares profited along with institutions - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 28 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 65.3 (%) |
| Shares Short | 916 (K) |
| Shares Short P.Month | 1,090 (K) |
| EPS | -11.66 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.02 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -51.4 % |
| Return on Equity (ttm) | -85.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.03 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -87 (M) |
| Levered Free Cash Flow | -46 (M) |
| PE Ratio | -3.02 |
| PEG Ratio | 0 |
| Price to Book value | 3.89 |
| Price to Sales | 0 |
| Price to Cash Flow | -11.24 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|